Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01492374 | Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease | PHASE1 | COMPLETED | 40 | — | — | Feb 1, 2012 | Oct 1, 2013 | Jul 24, 2014 | 24 | United States, Canada +3 |
| Arm | Type | Description |
|---|---|---|
| Arm 1: BMS-241027 (0.003 mg/kg) | EXPERIMENTAL | - |
| Arm 2: BMS-241027 (0.01 mg/kg) | EXPERIMENTAL | - |
| Arm 3: BMS-241027 (0.03 mg/kg) | EXPERIMENTAL | - |
| Arm 4: Placebo matching BMS-241027 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-241027 | DRUG | Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks |
| Placebo matching BMS-241027 | DRUG | Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks |
Inclusion Criteria: * Mild AD Subjects meeting National Institute of Neurological Disorders and Stroke - Alzheimer's Disease Related Disorders Association(NINCDS-ADRDA) and Diagnostic and Statistical Manual of Mental Disorders-Forth Edition, Text Revision (DSM-IV-TR) criteria * Mini-Mental State Ex...